Health

GE HealthCare's manganese MRI agent matched gadolinium, a route past China's rare earths

About 65 million contrast-enhanced MRI scans a year run on gadolinium, a rare earth whose export China licenses. A manganese substitute that matched the incumbent in GE HealthCare's Phase 2 trial opens a route off that chain for the company's highest-margin segment, if Phase 3 holds.

Vincent JiangVincent Jiangthree-minute read
Share
A patient on the table of a GE Signa MRI scanner while a technologist stands at the console in a hospital scanning room
A GE HealthCare Signa MRI scanner at Narayana Multispeciality Hospital in Jaipur, India. Roughly 65 million contrast-enhanced MRI scans a year use gadolinium agents, the market GE HealthCare hopes its manganese candidate can hold on to.

GE HealthCare−2.00% — GE HealthCare, down 2.00 percent today said on November 19 that mangaciclanol, its investigational manganese-based MRI contrast agent, met the primary endpoint of the LUMINA trial's Phase 2 stage: blinded independent readers found overall diagnostic preference similar between it and gadobutrol, the market-leading gadolinium agent 1. It was well tolerated, with no safety concerns identified, and the Phase 3 dose is set at 0.1 mmol/kg 1. The first patient was dosed at Mayo Clinic in April 2026, and the candidate carries the US Food and Drug Administration's Fast Track designation 1.

Sixty-five million scans a year ride on one rare earth

Around 65 million contrast-enhanced MRI procedures a year run on gadolinium agents, roughly a third of all MRI scans 1. GE HealthCare calls the rare earth largely dependent on Chinese mining and processing 1, and Beijing's April 2025 export licensing of seven medium and heavy rare earths, gadolinium among them, has stayed in force through every truce since 2. Manganese, an essential element the body already regulates, is available from multiple countries 1.

China's grip tightens to 97 percent down the rare-earth chain

Gadolinium sits at the end of a chain China already controls

  • Estimate
0%20%40%60%80%100%Mining and extraction70%Refining and processing90%Heavy rare-earth separation97%April 2025 licensing covers gadolinium
Data
Value
Mining and extraction (estimate)70%
Refining and processing (estimate)90%
Heavy rare-earth separation (estimate)97%
Estimated shares of global rare-earth output at each stage; gadolinium is a heavy rare earth. Sources: Tech Times relaying Motley Fool research and BISI estimates, November 2026.2

The hedge guards a 29.9 percent margin

Pharmaceutical Diagnostics, the unit that sells contrast agents, booked $846 million of third-quarter revenue, up 13.0 percent, or $97 million, as reported 3. Its segment EBIT margin, operating profit as a share of revenue, came to 29.9 percent, against 15.3 percent for the imaging segment, the highest of the company's three segments 3.

The contrast-agent unit earns twice the imaging unit's operating margin

0%10%20%30%Pharmaceutical DiagnosticsImagingGE HealthCare total14.6%29.9%
Data
Operating margin
Pharmaceutical Diagnostics29.9%
Imaging15.3%
GE HealthCare total14.6%
Operating profit as a share of revenue, third quarter ended 30 September 2026. Segment figures are segment EBIT; the company figure is total operating margin, which carries corporate costs the segments do not. Sources: GE HealthCare Form 10-Q, 28 October 2026, and quarterly figures from its SEC filings.3,7

The unit supports 140 million patient procedures a year 1, added a $138 million plant expansion in Cork, Ireland 1, and agreed in October to pay $945 million for SOFIE Biosciences, a 15-plant PET isotope network, with the antitrust review running toward a first-half 2027 close 4. Mangaciclanol's case is supply security for a segment that already runs on gadolinium agents, not new chemistry.

Parity is a low bar, and manganese has lost before

The release carries no price, no approval date and no Phase 3 budget, and its endpoint was similarity, not superiority 1. The data stay company-reported until December 1, when the images screen at the RSNA radiology congress in Chicago 1. Manganese has lost here before: Teslascan, an earlier agent for liver MRI, was withdrawn from the US market in 2003 and from Europe in 2012 for commercial reasons 5.

The incumbent is dug in: Bayer's Gadavist, the gadobutrol brand, has sold more than 44 million US vials since 2011 at the same 0.1 mmol/kg dose, in a cage rated at more than 1,000 years before it lets gadolinium go 6. GEHC shares slipped 1.14 percent on the day 1.

December 1 puts the images on the record

Watch December 1 at RSNA, when outside readers see the images the blinded readers saw 1. The open question is whether those readers stay indifferent in Phase 3, which widens the test from the brain and spine to the rest of the body 1.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading GEHC

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Eli Lilly Agreed to Buy Calytrix Bio for Up to $1.5 Billion, Its Latest Deal in a $32 Billion Year

    A $32 billion acquisition year rests on an $11 billion quarterly cash engine, but the deal headlines are "up to" figures and the balance sheet is already thinning. Whose money moves: anyone holding LLY at 31 times forward earnings into December 7 and January.

    Health

    Abridge lost AI scribing to Microsoft and Epic; its next market has a $100 million price from Wolters Kluwer

    Microsoft and Epic took two of every three new AI-scribe dollars this year, and Abridge, which built that market, is selling what comes after the note. The decision-support category it is moving into just got a public price, Wolters Kluwer's $100 million AgileMD deal, and that price is what Abridge's $6.69 billion private mark has to outrun.

    Health

    CMS's CRUSH rule reaches past Medicare into Molina's $42 billion Medicaid book

    The November 18 rout priced the proposal as a UnitedHealth-Humana Medicare bill. Molina is leaving that business, so for it the rule's weight falls on the Medicaid audit duties covering the $42 billion premium book that carries its $9.50 2027 earnings framework.

    Health

    AstraZeneca commits $200 million to Tempus AI through 2031 but can walk away for the shortfall

    A five-year, $200 million renewal from AstraZeneca gives Tempus AI a revenue floor it can book, filed days before a shareholder vote on a stock-funded acquisition, but the contract lets the drugmaker quit early by paying only the shortfall.

    Health

    OpenEvidence CEO tells medical students to take paper exams as OpenAI and Anthropic give doctors AI free

    Daniel Nadler built a $15 billion company on giving doctors AI answers free. On Monday he warned the doctors still training on his tool that AI erodes the skill that makes an answer worth having.

    Health

    Molina Healthcare jumps 8% on a CMS work-rule delay; director Steven Orlando sold 702 shares at $227.33

    A CMS work-rule delay bought Molina's Medicaid book time, not margin, and insiders including director Steven Orlando sold into the strength. New buyers are paying roughly 24 times a 2027 framework that is not yet guidance and must still be earned in February.

    Subscribe to TheInference for free